CRDL Cardiol Therapeutics

EQS-News: Cardiol Therapeutics begins Phase II study of CardiolRx for treatment of recurrent pericarditis

EQS-News: Cardiol Therapeutics
Cardiol Therapeutics begins Phase II study of CardiolRx for treatment of recurrent pericarditis

16.12.2022 / 18:26 CET/CEST
The issuer is solely responsible for the content of this announcement.

Contact Details

Proactive Canada

Proactive Canada


News Source: News Direct

16.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com
Language: English
Company: Cardiol Therapeutics
United States
ISIN: CA14161Y2006
EQS News ID: 1515789

 
End of News EQS News Service

1515789  16.12.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1515789&application_name=news&site_id=research_pool
EN
16/12/2022

Underlying

CRDLCardiol Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cardiol Therapeutics

 PRESS RELEASE
Free
CRDL Cardiol Therape...

Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Co...

Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate at the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA. Members of management will present on March 4, 2026, at 10:30 a.m. EST.A live webcast of the Company's presentation, as well as a webcast replay will be available under "Events & Presentations" in ...

February 25, 2026 1 EN
 PRESS RELEASE
Free
CRDL Cardiol Therape...

Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC H...

Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced the publication of results from its Phase II ARCHER study in ESC Heart Failure, a journal of the European Society of Cardiology.The peer-reviewed article reports results from a randomized, double-blind, placebo-controlled trial evaluating CardiolRx™, Cardiol's lead oral drug candidate, in 109 patients w...

February 10, 2026 1 EN
 PRESS RELEASE
Free
CRDL Cardiol Therape...

Cardiol Therapeutics Announces Closing of Bought Deal Financing and Fu...

Toronto, Ontario--(Newsfile Corp. - January 23, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has closed its previously announced private placement of units (the "Units") of the Company (the "Offering"), including the full exercise of the over-allotment option. Canaccord Genuity Corp. (the "Underwriter") acted as sole underwriter and sole bookrunner for the Offering. Pursuant to the Offer...

January 23, 2026 1 EN
 PRESS RELEASE
Free
CRDL Cardiol Therape...

Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in ...

Clinical trial infrastructure fully operational in the U.S. with more than 15 leading cardiovascular centers actively enrolling patients.Activation of additional top-tier clinical sites in Europe and Canada underway, further accelerating enrollment momentum.Full enrollment expected in Q2 2026.Toronto, Ontario--(Newsfile Corp. - January 13, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has...

January 13, 2026 1 EN
 PRESS RELEASE
Free
CRDL Cardiol Therape...

New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Impr...

Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with acute myocarditis.Results provide clinical evidence that CardiolRx™ reduces inflammation-driven structural damage in the heart, an important cause of heart failure progression.The ARCHER data strengthen the scientific and clinical rationale for Cardiol's lead Phase III program in recurrent pericarditis (MAVERIC) and support broader development across inflammatory cardiac conditions.Chronic inflamm...

December 1, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch